Comparison of the antibacterial activities of the quinolones Bay 12-8039, gatifloxacin (AM 1155), trovafloxacin, clinafloxacin, levofloxacin and ciprofloxacin

The Journal of Antimicrobial Chemotherapy
A Bauernfeind

Abstract

The in-vitro activities of the quinolones Bay 12-8039, gatifloxacin (AM 1155), trovafloxacin, clinafloxacin, levofloxacin and ciprofloxacin were compared. Gram-positive cocci were most susceptible to Bay 12-8039, clinafloxacin and trovafloxacin; Enterobacteriaceae and fastidious organisms were most susceptible to clinafloxacin [corrected]; Pseudomonas spp. were most susceptible to clinafloxacin and ciprofloxacin; anaerobes, Helicobacter pylori and Campylobacter jejuni were most susceptible to gatifloxacin, clinafloxacin and trovafloxacin. Against gram-positive cocci, the only agents that were more active than ciprofloxacin were those carrying an azabicyclo (trovafloxacin, Bay 12-8039), 3-amino-pyrrolidinyl (clinafloxacin) or 3-methyl-piperazinyl (gatifloxacin) moiety at position C7.

Citations

Jul 18, 2003·Current Infectious Disease Reports·Philippe Cottagnoud, Martin G. Täuber
Nov 30, 2000·Current Infectious Disease Reports·P Ball
Jun 19, 2001·Diagnostic Microbiology and Infectious Disease·R N JonesUNKNOWN SENTRY Antimicrobial Surveillance Program Participants Group (USA)
Dec 26, 2001·Diagnostic Microbiology and Infectious Disease·M BassettiV T Andriole
Oct 29, 1998·Diagnostic Microbiology and Infectious Disease·D J BiedenbachR N Jones
Feb 24, 2001·International Journal of Antimicrobial Agents·P C Appelbaum, P A Hunter
Dec 19, 2000·International Journal of Antimicrobial Agents·E HuczkoJ Fung-Tomc
Nov 30, 2002·International Journal of Antimicrobial Agents·I MilazzoA Speciale
Oct 26, 2000·Current Opinion in Microbiology·S M Bhavnani, C H Ballow
Mar 6, 1999·Current Opinion in Microbiology·I Chopra
Sep 13, 2000·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·D M Grasela
Mar 16, 2001·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·A Dalhoff
Mar 16, 2001·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·P D Lister
Mar 16, 2001·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·C KrasemannG Tillotson
Aug 13, 2002·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Ellie J C Goldstein
Feb 22, 2003·Surgical Infections·R L Nichols
Feb 19, 2005·Journal of Ocular Pharmacology and Therapeutics : the Official Journal of the Association for Ocular Pharmacology and Therapeutics·Harold JensenBrian Short
Nov 3, 2010·Journal of Ocular Pharmacology and Therapeutics : the Official Journal of the Association for Ocular Pharmacology and Therapeutics·Jeremy ShawAmilia Schrier
Dec 24, 2011·Journal of Ocular Pharmacology and Therapeutics : the Official Journal of the Association for Ocular Pharmacology and Therapeutics·Soon-Phaik Chee
Mar 11, 2008·Retina·McGregor N LottDennis M Marcus
Jan 16, 2009·Journal of Gastroenterology and Hepatology·Toshihiro NishizawaToshifumi Hibi

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Campylobacteriosis (ASM)

Campylobacteriosis is caused by the bacteria Campylobacter jejuni and is a common cause of gastroenteritis in humans. Discover the latest research on Campylobacteriosis here.

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.